Voyager Therapeutics
VYGR
125 hedge funds and large institutions have $569M invested in Voyager Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 10 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
69% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 29
58% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $683K
16% more funds holding
Funds holding: 108 → 125 (+17)
12% more capital invested
Capital invested by funds: $509M → $569M (+$60.1M)
6.01% more ownership
Funds ownership: 84.03% → 90.04% (+6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highline Capital Management
New York
|
+$16.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.4M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$10.7M |
| 4 |
AC
Armistice Capital
New York
|
+$8.54M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$29.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.7M |
| 3 |
Axa
Paris,
France
|
-$4.75M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.74M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.41M |
VYGR Hedge Fund Activity: Q2 2018 in Review
125 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2018, worth a combined $569M — up 12% from $509M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VYGR positions and 10 closed out — a net gain of 18 holders — while 49 added to existing stakes and 29 trimmed.
The largest buyer was Highline Capital Management, opening a new position worth an estimated $16.6M. The largest seller was TRV GP III, cutting an estimated $29.6M.
- 125 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2018, up from 108 in Q1 2018.
- Funds reported $569M of Voyager Therapeutics stock for Q2 2018, up 12% quarter-over-quarter.
- 28 funds opened new Voyager Therapeutics positions in Q2 2018 and 10 closed out, a net change of +18 holders.
- The largest Voyager Therapeutics buyer in Q2 2018 was Highline Capital Management, an estimated $16.6M added.
- The largest Voyager Therapeutics seller in Q2 2018 was TRV GP III, an estimated $29.6M sold.
Based on aggregated 13F filings for Q2 2018.